Embryonal Rhabdomyosarcoma in a Pediatric Patient: Therapeutic Target Identification
Protean BioDiagnostics to present on embryonal rhabdomyosarcoma in a pediatric patient.
Another rare pediatric soft tissue tumor was analyzed to determine therapeutic targets. Combining immunohistochemistry, OncoTargets pathway analysis that measures key signaling pathway activity, Follow It liquid biopsy, and structural chromosome aberration analysis by copy number variation uncovered that this patient was eligible for a novel clinical trial containing MEK and PD-L1 checkpoint inhibitors.
This abstract was originally presented on May 6th at ASPHO.
About Protean BioDiagnostics
Protean BioDiagnostics is revolutionizing modern healthcare with our Protean MAPS™ system, which integrates health screening, diagnostics, treatment guidance, and tele-medicine backed decision support.
We collaborate with physicians and health groups to support them in providing the best possible care for their patients, regardless of where they live.